TDNA vs XBI
T. Rowe Price Biotech ETF against State Street SPDR S&P Biotech ETF: cost, size, returns, what they hold and how much of it is the same.
Fee gap
—
same fee
1-year return gap
—
Larger fund
XBI
$9.9B
Side by side
| TDNA | XBI | |
|---|---|---|
| Fund | T. Rowe Price Biotech ETF | State Street SPDR S&P Biotech ETF |
| Issuer | T. Rowe Price | State Street SPDR |
| Category | Biotech & Health Innovation | Biotech & Health Innovation |
| Expense ratio | — | 0.35% |
| Assets | — | $9.9B |
| Average daily dollar volume | $44K | $1.4B |
| Listed | Sep 16, 2026 | Jan 31, 2006 |
| FrenzyCap score | — | 96 |
| 1-month return | — | −1.9% |
| 3-month return | — | −1.0% |
| Year to date | — | +26.1% |
| 1-year return | — | +45.8% |
| 30-day volatility | 28.7% | 27.0% |
| Worst drawdown, 1 year | −7.9% | −11.9% |
| Trailing 12-month yield | — | 0.35% |
| Holdings | — | 166 |
| Top 10 weight | — | 16.9% |
| Look-through P/E | — | — |
| Holdings vs fair value | — | +5.8% |
| Holdings above 200-day average | — | 62% |
| Net flow, latest 3 reported months | — | +$1.3B thru Jun 2026 |
| 30-day implied volatility | — | 31.2% |
| Holdings as of | as of Oct 8, 2026issuer data |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
More: full overlap table · TDNA holdings · XBI holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.